Pharmaverse

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

→

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CTGOV9/25/2026, 5:06:40 AM

Trial enrollment change

enrollment_type

ESTIMATED

→

ACTUAL

CTGOV9/25/2026, 5:06:40 AM

Trial status change

overall_status

Recruiting

→

Active, not recruiting

CTGOV9/29/2026, 5:05:08 AM

Trial site count change

location_count

93

→

94

CTGOV9/29/2026, 5:06:29 AM

Trial enrollment change

enrollment_type

ESTIMATED

→

ACTUAL

CTGOV9/29/2026, 5:06:29 AM

Trial endpoint change

primary_outcomes

[object Object],[object Object],[object Object],[object Object]

→

[object Object],[object Object],[object Object],[object Object]

CTGOV9/30/2026, 5:06:15 AM

Trial endpoint change

primary_outcomes	[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
secondary_outcomes	[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CTGOV9/30/2026, 5:06:15 AM

Trial results posted

results_first_posted	null	→	2026-09-29
adverse_events_module_present	false	→	true

EDGAR9/30/2026, 5:30:00 AM

Filing 8k material

CTGOV10/2/2026, 5:05:01 AM

Trial site count change

location_count

94

→

104

CTGOV10/7/2026, 5:06:30 AM

Trial enrollment change

enrollment_type	ESTIMATED	→	ACTUAL
enrollment_count	285000	→	41060

CTGOV10/7/2026, 5:06:30 AM

Trial status change

overall_status

Active, not recruiting

→

Completed

CTGOV10/7/2026, 5:06:30 AM

Trial completion date change

completion_date	2026-08	→	2026-09-05
primary_completion_date	2026-08	→	2026-08-26

EDGAR10/7/2026, 5:30:00 AM

Insider transaction

CTGOV10/9/2026, 5:07:07 AM

Trial enrollment change

enrollment_count

932

→

931

CTGOV10/9/2026, 5:07:07 AM

Trial endpoint change

primary_outcomes	[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object],[object Object]
secondary_outcomes	[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object]

CTGOV10/9/2026, 5:07:07 AM

Trial results posted

results_first_posted	null	→	2026-10-08
adverse_events_module_present	false	→	true

MARKET10/9/2026, 5:30:00 AM

Unusual move

CTGOV10/10/2026, 5:05:35 AM

Trial site count change

location_count

104

→

117

CTGOV10/11/2026, 5:04:55 AM

Trial registered

record_exists

false

→

true

CTGOV10/14/2026, 5:06:06 AM

Trial eligibility change

eligibility_criteria

Key Inclusion Criteria: * Arm 1: Histologically confirmed advanced or metastatic cancer (melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal carcinoma, head and neck squamous cell carcinoma (HNSCC), urinary bladder cancer (UBC), colon/rectal adenocarcinomas, gastric, ovarian, cervical, and endometrial carcinomas) with measurable disease as determined by Response Evaluation Criteria In Solid Tumors volume 1.1 (RECIST v1.1) and have completed or refused all standard therapies (no limit to prior lines of therapy). Participants must have a tumor lesion amenable to biopsy, or alternatively archival tumor tissue is acceptable as long as the collection date is within one year of the enrollment date. * Arm 2: Histologically confirmed advanced or metastatic cancer (melanoma, NSCLC, esophageal carcinoma, HNSCC, urothelial/bladder carcinoma, gastric, colon/rectal adenocarcinomas, ovarian, cervical, and endometrial carcinomas \[Note: HCC not included\]) with measurable disease as determined by RECIST v1.1 and have completed or refused all standard therapies (no more than 5 prior lines of therapy). Participants must have a tumor lesion amenable to biopsy, or alternatively archival tumor tissue is acceptable if no intervening systemic therapy was received. * Arm 2: Participant life expectancy of ≥90 days. * Arm 1 and Arm 2: Participant has an Eastern Cooperative Oncology Group performance status of ≤1. * Arm 1 and Arm 2: Participant has adequate hematological and biological function. * Arm 1 and Arm 2: Participants who could become pregnant: negative pregnancy test within 24 hours before the first dose of study treatment. Key Exclusion Criteria: * Arm 1 and Arm 2: Participant has active central nervous system tumors or metastases * Arm 1 and Arm 2: Participant has received treatment with prohibited medications/treatments (that is, concurrent anticancer therapy including other chemotherapy, hormonal anticancer therapy, biologic therapy, or immunotherapy) or investigational agents within 5 half-lives or 14 days prior to the first day of study treatment (Cycle 1 Day 1), whichever is shorter. * Arm 1 and Arm 2: Participant has required the use of immunosuppressive doses of systemic steroids or absorbed topical steroids (doses \>10 milligrams \[mg\] prednisone daily equivalent) within 2 weeks before study treatment administration or currently requiring maintenance doses of \>10 mg prednisone or equivalent per day. * Arm 1 and Arm 2: Participant has any plan to receive a live attenuated vaccine during study treatment or has received a live vaccine within 30 days before the first dose of study treatment. * Arm 1 and Arm 2: Participant has reversible toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline. Any unresolved toxicity National Cancer Institute Common Terminology Criteria for Adverse Events Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and prespecified laboratory values. * Arm 1 and Arm 2: Participant has any unstable or clinically significant concurrent medical/psychiatric illness or social situation that would limit compliance with study requirements or compromise the ability of the participant to provide written informed consent, per the discretion of the Investigator. * Arm 1 and Arm 2: Participant has concurrent enrollment in another clinical study (unless it is an observational noninterventional clinical study). Note: Other inclusion and exclusion criteria may apply.

EDGAR10/16/2026, 5:30:00 AM

Insider transaction

CTGOV10/17/2026, 5:05:49 AM

Trial site count change

location_count

242

→

244

CTGOV10/18/2026, 5:05:27 AM

Trial registered

record_exists

false